Dogwood Therapeutics Announces $5 Million Private Placement With CK Life Sciences

Bitget2026/10/19 12:39

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Dogwood Therapeutics agreed to a $5 million private placement with its largest shareholder, a subsidiary of CK Life Sciences.
The transaction involves 4,098,360 shares of Common Stock at $1.22 per share.
Closing is expected by October 29, 2026; no warrants or other derivative securities are included.
Proceeds will fund Halneuron Phase 3 preparations and general corporate needs, extending operational runway through March 2027.
Topline data from the Halneuron Phase 2b chemotherapy-induced neuropathic pain trial are expected in November 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190830PRIMZONEFULLFEED9848342) on October 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Dogwood Therapeutics Announces $5 Million Private Placement With CK Life Sciences

You may also like

Crypto prices